Sudeep Pharma Limited has submitted the transcript of its Q3FY26 earnings conference call to stock exchanges, following the company's impressive financial performance and strategic announcements. The earnings call, held on February 9, 2026, provided detailed insights into the company's operational and financial achievements for the third quarter and nine months ended December 31, 2025.

Strong Financial Performance Continues

The earnings call transcript reinforced the company's robust Q3FY26 performance, with management highlighting sustained growth across key metrics. The company's consolidated financial results demonstrated impressive momentum across all business segments.

Management Commentary on Growth Drivers

During the earnings call, Managing Director Sujit Bhayani emphasized the company's 36-year journey and evolution from mineral excipients manufacturer to a diversified portfolio serving over 100 countries. Director Shanil Bhayani provided detailed insights into geographic performance, highlighting strong growth in Asia-Pacific driven by deeper collaboration with leading FMCG and infant nutrition customers.

Business Segment Performance

The earnings call revealed that export business contributed 62% of revenue while domestic business accounted for 38% in Q3FY26. The specialty ingredients segment contributed 41% of revenue, demonstrating strong momentum, while pharma, food and nutrition contributed 59%.

Battery Materials Strategic Initiative

The earnings call provided extensive details on Sudeep Advanced Materials (SAM), the company's battery materials division. Management highlighted progress with 34 customers across the battery value chain, with 70% having approved and validated Sudeep samples. The Dahej facility groundbreaking ceremony was conducted on January 23, 2026, with Phase 1 capacity of 25,000 MT scheduled for early 2027 commissioning.

Capacity Expansion and Future Outlook

CFO Ketan Vyas confirmed that the Nandesari Greenfield facility with 51,200 MT capacity remains on track for March 2026 commissioning. The facility will enable production of higher-value molecules including gluconates, glycinates and citrines. Management expressed confidence in sustaining current growth momentum with stable margin profiles.

Regulatory Compliance

Company Secretary Dimple Mehta submitted the earnings call transcript to NSE (Scrip Symbol: SUDEEPPHRM) and BSE (Scrip Code: 544619) on February 12, 2026, under Regulation 30 of SEBI LODR Regulations. The transcript is also available on the company's website at https://www.sudeeppharma.com/ .

Sudeep Pharma Limited has made the audio recording of its Q3FY26 earnings call available to stakeholders following the successful completion of the conference call on February 9, 2026. The pharmaceutical company announced the availability through a regulatory filing under Regulation 30 of the SEBI Listing Regulations, 2015.

Earnings Call Details and Access

The company conducted its earnings call as scheduled on February 9, 2026, at 11:00 AM IST, focusing on operational and financial performance for the quarter and nine months ended December 31, 2025. The complete audio recording has been uploaded on the company's official website for immediate access by investors, analysts, and other stakeholders.

Regulatory Compliance and Documentation

Sudeep Pharma has informed both NSE and BSE about the audio recording availability through proper regulatory channels. Company Secretary and Compliance Officer Dimple Mehta signed the official communication on February 9, 2026, ensuring full compliance with listing regulations.

Next Steps and Additional Documentation

The company has indicated that a detailed transcript of the earnings call will be submitted separately to the stock exchanges. This will provide stakeholders with comprehensive written documentation of the management discussions and Q&A session that took place during the conference call.